Clinical Trials Logo

Urinary Tract Infections clinical trials

View clinical trials related to Urinary Tract Infections.

Filter by:

NCT ID: NCT05545137 Completed - Clinical trials for Uncomplicated Urinary Tract Infection

Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection

Start date: September 29, 2022
Phase: Phase 3
Study type: Interventional

the purpose of this study is to evaluate the efficacy and safety of pivmecillinam hydrochloride tablets in the treatment of uncomplicated urinary tract infection in China

NCT ID: NCT05513677 Completed - Clinical trials for Urinary Tract Infections

Characterisation of Biofilm Growth on Coated vs. Uncoated Urinary Catheter Surfaces in Normal Clinical Use

PRO30CSP
Start date: August 14, 2018
Phase: N/A
Study type: Interventional

1. Evaluated Patients: 5 patients (Convenience sample: non-blinded, non-randomised) Selection follows documented hospital protocols for routine catheterisation 2. Measured Patients: 30 patients (Convenience sample: non-blinded and non-randomised) - 20 who receive the M4D coated catheter. - 10 who receive the standard uncoated catheters used in routine patient care.

NCT ID: NCT05397782 Completed - Clinical trials for Urinary Tract Infections

Effects of Flourish on Recurrent Urinary Tract Infection

Start date: September 26, 2022
Phase: N/A
Study type: Interventional

An over-the-counter vaginal care system is being tested to see if it may be effective in preventing recurrence of symptomatic urinary tract infection (UTI) in women who have had multiple UTIs within the past year.

NCT ID: NCT05385536 Completed - Clinical trials for Urinary Tract Infections

Evaluating UTI Outcomes in at Risk Populations

At Risk
Start date: July 18, 2022
Phase:
Study type: Observational

This is a multicenter, observational comparative cohort, study to evaluate the UTI related adverse event rates between Guidance® UTI clinical pathway versus the current traditional clinical pathways for urine testing.

NCT ID: NCT05376670 Completed - Clinical trials for Urinary Tract Infections

Patient Satisfaction and Long-term Safety of Intravesical Aminoglycoside Instillations in UTI Prevention

INSTILMENT
Start date: April 20, 2022
Phase:
Study type: Observational

Antimicrobial prophylactic treatment of recurrent UTI is limited by emerging resistance, antibiotic allergies and intolerances. Intravesical aminoglycoside instillations (IAI) have been shown to reduce recurrence rate, without a short-term decline in kidney function or hearing. Thus far, treatment satisfaction has not yet been assessed, while this may play an important role in treatment adherence and persistence. Moreover, there is no data on the long-term safety of IAI, e.g. regarding the development of (pre)malignant bladder lesions.

NCT ID: NCT05365906 Completed - Clinical trials for Urinary Tract Infections

UTI Reference Standard: Delphi Method

ORACLE
Start date: April 12, 2022
Phase:
Study type: Observational

This study is set up by an international core group consisting of infectious disease specialists, geriatricians, urologists, microbiologists, emergency physicians and primary care physicians to develop a consensus-based research definition of urinary tract infections. The absence of such a reference standard leads to misclassification bias and heterogeneity between studies making progress in the field of UTI difficult, for example with much needed near patient diagnostic tests.

NCT ID: NCT05309317 Completed - Nurse's Role Clinical Trials

Preventing Catheter-Associated Urinary Tract Infections With a Virtual Simulation Game

CAUTI-VSG
Start date: May 21, 2022
Phase: N/A
Study type: Interventional

Objective: The purpose of this study was to investigate the effectiveness of a virtual simulation game in improving nursing students' knowledge and abilities in preventing catheter-associated urinary tract infection (CAUTI). Method: The study was designed as a parallel-group, randomized controlled trial. A pre-test on knowledge and abilities will be administered to all students participating in the study. Following the pre-test evaluation, a training session on "CAUTI Prevention" will be held. The present training approach (lecture method) in the curriculum will be employed in this session. Following the training, the students in the sample group will be randomly divided into the experimental group (students using virtual simulation game application) and the control group (students learning with the existing education method) based on their general weighted grade averages using the stratified randomized approach. The experimental group will play the virtual simulation game for seven days. Knowledge and competence assessments (post-test) of the control and experimental groups will be conducted seven days following the training. The virtual simulation game application will be evaluated by the students in the experimental group after the post-test evaluations. The students' positive, negative, and constructive feedback on the virtual simulation game will be solicited during the assessment. In addition, these students will score in a 5-point Likert type to evaluate the statements about the virtual simulation game. Hypothesis: H0-1: There is no difference in knowledge about preventing CAUTI between students using the virtual simulation game method and students in the control group. H1-1: There is a difference in knowledge about preventing CAUTI between students using the virtual simulation game method and students in the control group. H0-2: There is no difference in CAUTI prevention skills between students using the virtual simulation game method and students in the control group. H1-2: There is a difference in CAUTI prevention skills between students using the virtual simulation game method and students in the control group.

NCT ID: NCT05259683 Completed - Sepsis Clinical Trials

Febrile Infant Diagnostic Assessment and Outcome Study

FIDO
Start date: August 1, 2022
Phase:
Study type: Observational

Febrile infants under 3 months of age represent a high risk group for invasive bacterial infection (IBI) and UTI with approximately 10-20% having bacteremia, meningitis or urinary tract infection. The assessment of febrile infants is challenging, and current National Institute for Health and Care Excellence (NICE) guidance advocates a cautious approach with the majority of infants requiring a septic screen, parenteral broad-spectrum antibiotics, and admission to hospital. Internationally there is significant variation in the approach to febrile infants with European and USA guidance advocating a tailored approach based on clinical features and biomarker testing. None of the available clinical decision aids (CDA) have been validated in a UK and Irish cohort. The main objectives of the FIDO study are to report performance accuracy of CDA in a UK (United Kingdom) and Irish population, and describe the aetiology of SBI in young infants. The FIDO study is a prospective observational cohort study of infants under 90 days of age with a measured fever greater than 38 Centrigrade within 24 hours of presentation. The study will run for approximately 12 months and recruit a minimum of 1000 participants.Symptoms, clinical features and laboratory results will be recorded on an electronic case report form (CRF) by the attending clinician.

NCT ID: NCT05219877 Completed - Clinical trials for Urinary Tract Infections

Effectiveness of Preurodynamic With Posturodynamic Levofloxacin on the Incidence of UTI

Start date: February 4, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to compare the effectiveness of preoperative single dose of levofloxacin with postoperative levofloxacin for three days on the incidence of urinary tract infections (UTI) after urodynamic examination.

NCT ID: NCT05109455 Completed - Clinical trials for Kidney Transplant Infection

Effects of a Food Supplement in the Prevention of Urinary Tract Infections in Kidney Transplant Patients.

MANOTRAS
Start date: April 16, 2019
Phase: Phase 4
Study type: Interventional

The incidence of Urinary tract infections (UTIs) is very high in kidney transplant patients. Most UTIs occur during the first six months (82% within the first three months) of kidney transplantation and are frequently recurrent. The component D-mannose of our authorized food supplement acts by inhibiting the adherence of E.coli to the urothelium. It also has a controlled release formula that ensures the presence in urine of D-mannose and the other components during 24 hours. This is the reason why this experimental study aims to demonstrate that the oral intake of this food supplement is effective in the prevention of UTIs in kidney transplant patients.